Neurofibromatosis is a genetic condition that affects the nervous system and skin, causing tumors to grow along nerves throughout the body. While there is no cure, treatment focuses on managing symptoms, preventing complications, and improving quality of life through a combination of monitoring, surgery, and newer drug therapies currently being tested in clinical trials.

How Treatment Approaches Help Manage Life with Neurofibromatosis

The goal of treating neurofibromatosis is not to cure the condition, but rather to help people live as comfortably and fully as possible. This means controlling symptoms when they appear, slowing down tumor growth when necessary, and catching complications early before they become serious. Treatment needs change throughout a person’s life because neurofibromatosis affects people differently at different ages. A child might need help with learning difficulties or eye problems, while a teenager might struggle with visible skin tumors, and an adult might face pain or mobility issues.

Because neurofibromatosis can affect many parts of the body—from the brain and spinal cord to the skin, bones, eyes, and blood vessels—treatment usually involves a team of different specialists working together. This team might include neurologists who specialize in the nervous system, eye doctors called ophthalmologists, bone specialists known as orthopedists, surgeons, skin doctors called dermatologists, and others. Each specialist focuses on different aspects of the condition to provide comprehensive care.

Standard treatments that have been used for many years remain the foundation of care, but medical research continues to develop promising new therapies. Some of these newer treatments are being tested in clinical trials, which are carefully controlled research studies that test whether new drugs or approaches are safe and effective. Clinical trials offer hope for better treatment options, especially for complications that have been difficult to manage with existing therapies.

Standard Treatment Approaches for Neurofibromatosis

The cornerstone of managing neurofibromatosis is regular monitoring and checkups. Medical guidelines recommend that people with neurofibromatosis type 1 see their doctors at least once a year, and children may need more frequent visits—every six to twelve months. During these appointments, doctors check the skin for new tumors or changes in existing ones, measure blood pressure to detect hypertension (high blood pressure), assess growth and development in children, examine the spine and bones for problems like scoliosis (curved spine), and perform neurological examinations to detect any nerve-related issues.^[1][6]

Eye examinations are particularly important and should happen annually for children and every two years for adults. Eye doctors look for tiny bumps on the colored part of the eye called Lisch nodules, which do not affect vision but indicate the presence of neurofibromatosis. More importantly, they screen for tumors on the optic nerve called optic gliomas, which can develop in childhood and potentially cause vision loss if not detected and treated early. When optic gliomas are found and causing problems, treatment typically involves chemotherapy to shrink the tumor and preserve vision.^[8][9]

Blood pressure monitoring is essential because people with neurofibromatosis can develop high blood pressure for various reasons. Sometimes it results from tumors in the adrenal glands called pheochromocytomas, which release hormones that raise blood pressure. Other times, narrowing of the arteries to the kidneys causes hypertension. When high blood pressure is detected, doctors investigate the cause through urine tests to check for excess hormones and imaging tests to look at the kidney arteries. Treatment depends on the underlying cause but may include blood pressure medications or procedures to open narrowed arteries.^[13]

For visible tumors on or under the skin called neurofibromas, surgery is one of the most common procedures performed. These small, pea-sized bumps can appear anywhere on the body and tend to increase in number during the teenage years and throughout adult life. While these tumors are not cancerous, people sometimes choose to have them removed if they cause pain, itching, or if the person feels self-conscious about their appearance. Surgery involves cutting out the tumors, though they may grow back because the underlying genetic condition remains. Newer technologies using lasers can remove small skin neurofibromas without traditional surgery, which may leave less scarring.^[13]

Larger, more complex tumors called plexiform neurofibromas present greater challenges. These tumors involve multiple nerves and can grow into surrounding tissues. About 50% of people with neurofibromatosis type 1 develop at least one plexiform neurofibroma, and these tumors have about a 10-15% chance of becoming cancerous over a person’s lifetime. Surgery to remove plexiform neurofibromas is difficult because they intertwine with normal nerves and tissues. Complete removal often is not possible without damaging nerves and causing weakness, numbness, or other problems. Surgeons may remove part of a large plexiform neurofibroma if it is pressing on organs, causing pain, or showing signs of becoming cancerous.^[1][4]

Bone problems require orthopedic care. Some children with neurofibromatosis develop curved or bowed leg bones, spinal curvature, or abnormal bone development. Treatment depends on the severity and location of the bone problem. Mild scoliosis may be monitored or treated with braces, while severe cases may require surgery to straighten and stabilize the spine. Bone defects in the legs sometimes need surgical correction and may involve using rods or other devices to support proper bone growth and prevent fractures.^[16]

Learning difficulties and behavioral issues like attention-deficit/hyperactivity disorder occur in many children with neurofibromatosis. Educational support, including special education services, tutoring, and accommodations at school, helps children learn effectively. Some children may benefit from medications used to treat ADHD, though these do not treat the neurofibromatosis itself—they help manage attention and behavior problems.^[2]

Pain management becomes increasingly important as people with neurofibromatosis age. Tumors pressing on nerves can cause chronic pain that affects daily activities and quality of life. Doctors may prescribe pain medications, including over-the-counter options for mild pain or stronger prescription medications for severe pain. Some people find relief through physical therapy, which helps maintain movement and strength, or through complementary approaches like biofeedback, a technique that helps people learn to control certain body responses to reduce pain.^[17]

Promising New Treatments Being Tested in Clinical Trials

One of the most exciting developments in neurofibromatosis treatment involves drugs called MEK inhibitors. To understand how these work, it helps to know that neurofibromatosis type 1 is caused by a mutation in a gene that normally produces a protein called neurofibromin. This protein acts as a tumor suppressor, helping to control cell growth. When the gene is mutated, cells don’t get proper signals to stop dividing, leading to tumor formation. The lack of neurofibromin causes increased activity in a cellular signaling pathway called the RAS pathway, which tells cells to grow and multiply. MEK inhibitors work by blocking a specific step in this overactive pathway, essentially putting the brakes on excessive cell growth.^[7][12]

The MEK inhibitor called selumetinib has shown particularly promising results for treating plexiform neurofibromas in children and young adults. Clinical trials found that selumetinib can shrink these tumors, reducing pain and improving quality of life. The drug is taken as capsules twice daily and works by targeting the specific molecular pathway that drives tumor growth in neurofibromatosis. In studies, many patients experienced significant tumor shrinkage—some plexiform neurofibromas decreased in size by 20% or more. Beyond just making tumors smaller, patients reported improvements in pain levels and ability to move and function in daily activities.^[11][12]

Selumetinib is now approved for use in children under 18 years old with symptomatic, inoperable plexiform neurofibromas. However, research continues to study whether it works equally well in adults, and clinical trials are ongoing for adult patients. The treatment does come with side effects, which doctors monitor carefully. Common side effects include skin rashes, diarrhea, nausea, fatigue, and changes in how the heart functions that can be detected on tests. Despite these side effects, many patients and families feel the benefits—reduced tumor size, less pain, and better quality of life—outweigh the risks.^[12]

Other MEK inhibitors are also being studied in clinical trials. Different versions of these drugs may work slightly differently or have different side effect profiles. Researchers are testing various MEK inhibitors to find which ones work best for different types of neurofibromatosis tumors and complications. These trials typically occur in phases. Phase I trials focus on safety, determining what doses can be given without causing unacceptable side effects. Phase II trials test whether the drug actually works against the disease and continue monitoring safety. Phase III trials compare the new treatment to current standard treatments to see if it offers advantages.^[12]

Beyond MEK inhibitors, researchers are exploring other targeted therapies that interfere with different parts of the abnormal signaling pathways in neurofibromatosis cells. These experimental drugs aim to block tumor growth through different mechanisms. Some target other steps in the RAS pathway, while others focus on different cellular signals that contribute to tumor formation. Scientists are also investigating combination therapies, where two or more drugs with different mechanisms work together to control tumor growth more effectively than any single drug alone.^[12]

Clinical trials for neurofibromatosis treatments are being conducted at specialized medical centers in various countries, including the United States, Europe, and other regions. To participate in a clinical trial, patients typically need to meet specific eligibility criteria. These criteria often include having a confirmed diagnosis of neurofibromatosis type 1, having specific types of tumors or complications, being within certain age ranges, and meeting health requirements. Doctors at specialized neurofibromatosis centers can provide information about available trials and help determine whether a patient might be eligible to participate.^[11]

For optic gliomas—tumors on the nerves that control vision—standard treatment has long been chemotherapy when the tumors threaten vision or cause other problems. However, researchers are now testing whether MEK inhibitors might also work for these brain tumors. Early studies suggest that blocking the same overactive RAS pathway might help shrink optic gliomas and preserve or improve vision, potentially with fewer side effects than traditional chemotherapy. These investigations are still in relatively early stages, and more research is needed to confirm effectiveness and safety.^[12]

Another area of research involves better understanding which plexiform neurofibromas are most likely to become cancerous. Scientists are studying the molecular and genetic changes that occur when benign tumors transform into malignant ones. This research may eventually lead to tests that can predict which tumors need more aggressive monitoring or earlier treatment. Additionally, researchers are developing treatments specifically for malignant peripheral nerve sheath tumors, the cancers that can develop from neurofibromas. These cancers are difficult to treat, and current approaches involve surgery, radiation therapy, and chemotherapy, but outcomes remain challenging.^[12]

Most common treatment methods

• Regular Monitoring and Surveillance
  • Annual or more frequent medical checkups to monitor for new tumors and complications
  • Regular eye examinations to detect optic nerve tumors and vision problems
  • Blood pressure monitoring to identify hypertension early
  • Growth and development assessment in children
  • Neurological examinations to detect nerve problems
• Surgical Interventions
  • Removal of cutaneous neurofibromas that cause pain, itching, or cosmetic concerns
  • Partial removal of plexiform neurofibromas when they press on organs or become symptomatic
  • Laser therapy for small skin neurofibromas to reduce scarring
  • Orthopedic surgery for bone deformities, scoliosis, or bowed legs
  • Procedures to address complications like narrowed arteries
• Targeted Drug Therapy (MEK Inhibitors)
  • Selumetinib for treating plexiform neurofibromas in children and young adults
  • Other MEK inhibitors being tested in clinical trials for various tumor types
  • Drugs work by blocking overactive RAS signaling pathway that drives tumor growth
  • Can shrink tumors and reduce pain and improve quality of life
• Chemotherapy
  • Standard treatment for optic gliomas that threaten vision
  • Used for certain brain and spinal cord tumors
  • May be combined with other treatments for malignant tumors
• Symptom Management
  • Pain medications ranging from over-the-counter to prescription options
  • Blood pressure medications for hypertension
  • ADHD medications for attention and behavioral problems
  • Physical therapy to maintain mobility and strength
  • Biofeedback and complementary approaches for pain control
• Educational and Psychological Support
  • Special education services and school accommodations for learning difficulties
  • Therapy and counseling to address self-esteem and social challenges
  • Support groups and camps for children and families
  • Mental health services for anxiety and depression
• Radiation Therapy
  • Beam of radiation used to treat small tumors or tumor remnants after surgery
  • Applied when surgical removal is not feasible or complete
  • Used selectively due to potential long-term effects